Evofem Biosciences, Inc. SEC filings EVFM
Evofem Biosciences, Inc. has 802 filings in SEC EDGAR's recent list, going back to Sep 12, 2014. Its latest annual report, Form 10-K, was filed on Mar 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 29, 2025 | Oct 29, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 20, 2025 | Oct 20, 2025 |
| DEFA14A | Additional proxy material | Sep 19, 2025 | — |
| DEFA14A | Additional proxy material | Sep 9, 2025 | — |
| DEFM14A | Filing | Sep 8, 2025 | — |
| PREM14A | Filing | Aug 26, 2025 | Aug 26, 2025 |
| DEF 14C | Information statement | Aug 6, 2025 | Aug 5, 2025 |
| PREM14A | Filing | Jul 24, 2025 | Jul 24, 2025 |
| PRE 14C | Filing | Jul 9, 2025 | Jul 9, 2025 |
| PRE 14A | Preliminary proxy statement | Sep 23, 2024 | Sep 23, 2024 |
| DEF 14A | Proxy statement | Aug 29, 2023 | Aug 29, 2023 |
| PRE 14A | Preliminary proxy statement | Aug 11, 2023 | Aug 10, 2023 |
| DEF 14A | Proxy statement | May 1, 2023 | Jun 20, 2023 |
| DEFA14A | Additional proxy material | Feb 17, 2023 | — |
| DEF 14A | Proxy statement | Feb 15, 2023 | Mar 15, 2023 |
| PRE 14A | Preliminary proxy statement | Jan 27, 2023 | Jun 22, 2022 |
| DEFA14A | Additional proxy material | Apr 7, 2022 | — |
| DEFA14A | Additional proxy material | Apr 7, 2022 | — |
| DEFA14A | Additional proxy material | Apr 7, 2022 | — |
| DEF 14A | Proxy statement | Mar 30, 2022 | Mar 30, 2022 |
| PRE 14A | Preliminary proxy statement | Mar 18, 2022 | Mar 18, 2022 |
| DEFA14A | Additional proxy material | Dec 9, 2021 | — |
| DEFA14A | Additional proxy material | Dec 8, 2021 | — |
| DEFA14A | Additional proxy material | Nov 22, 2021 | — |
| DEF 14A | Proxy statement | Nov 9, 2021 | Dec 8, 2021 |
| PRE 14A | Preliminary proxy statement | Oct 29, 2021 | Oct 29, 2021 |
| DEFA14A | Additional proxy material | Apr 26, 2021 | — |
| DEFA14A | Additional proxy material | Mar 29, 2021 | — |
| DEF 14A | Proxy statement | Mar 29, 2021 | Mar 29, 2021 |
| DEF 14A | Proxy statement | May 8, 2020 | Jun 18, 2020 |
| DEFA14A | Additional proxy material | May 1, 2020 | — |
| PRE 14A | Preliminary proxy statement | Apr 28, 2020 | Jun 18, 2020 |
| DEFA14A | Additional proxy material | Mar 30, 2020 | — |
| DEF 14A | Proxy statement | Mar 30, 2020 | May 12, 2020 |
| DEF 14A | Proxy statement | Apr 24, 2019 | Jun 5, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2019 | Jun 5, 2019 |
| DEFA14A | Additional proxy material | Mar 21, 2018 | — |
| DEF 14A | Proxy statement | Mar 21, 2018 | May 8, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 20, 2017 |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 16, 2016 |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 16, 2015 |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EVFM (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1618835
- Former names
- Neothetics, Inc. (until Jan 5, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.